Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
Subscribe to our Newsletter
Oligonucleotide Therapeutics Society
c/o Event Innovations, Inc.
4377 Newport Avenue
San Diego, CA 92107, USA
- (619) 795-9458
info@oligotherapeutics.org
Resources
© Copyright 2012 – 2022 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing